Kobo Biotech Ltd

Kobo Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Kobo Biotech Ltd

₹ 4.08 0.00%
29 Apr 10:15 a.m.
avonlifesciences.com BSE: 531541
About

Kobo Biotech is engaged in the business of Pharmaceutical products.

[ add key points ]
Website BSE
  • Market Cap ₹ 9.72 Cr.
  • Current Price ₹ 4.08
  • High / Low ₹ 6.01 / 2.04
  • Stock P/E
  • Book Value ₹ 23.6
  • Dividend Yield 0.00 %
  • ROCE -4.10 %
  • ROE -49.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.17 times its book value

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of -2.76% over last 3 years.
  • Company has high debtors of 671 days.
  • Working capital days have increased from 253 days to 534 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014
162 287 404 103
133 238 361 104
Operating Profit 29 49 43 -1
OPM % 18% 17% 11% -1%
0 0 0 0
Interest 13 21 18 24
Depreciation 6 11 10 10
Profit before tax 10 18 15 -34
Tax % 0% 11% 8% -2%
10 16 14 -35
EPS in Rs 4.37 6.72 6.22 -15.48
Dividend Payout % 23% 15% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -14%
TTM: -74%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -355%
Stock Price CAGR
10 Years: -8%
5 Years: 0%
3 Years: -13%
1 Year: 51%
Return on Equity
10 Years: %
5 Years: %
3 Years: -3%
Last Year: -49%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014
Equity Capital 22 22 22 22
Reserves 39 51 65 31
131 118 182 179
57 154 142 163
Total Liabilities 250 346 412 396
110 100 108 104
CWIP 0 13 3 2
Investments 0 0 0 0
140 232 301 290
Total Assets 250 346 412 396

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014
64 37 7
-14 -7 -5
-27 -38 -13
Net Cash Flow 23 -9 -11

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2012 Mar 2013 Mar 2014
Debtor Days 143 187 185 671
Inventory Days 179 79 66 300
Days Payable 115 203 111 468
Cash Conversion Cycle 207 62 140 503
Working Capital Days 195 88 137 534
ROCE % 20% 14% -4%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
44.95% 44.95% 44.95% 44.95% 44.95% 44.95% 44.95% 44.95% 44.95% 44.95% 44.95% 44.95%
0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66% 0.66%
54.39% 54.39% 54.39% 54.39% 54.39% 54.39% 54.39% 54.40% 54.39% 54.39% 54.37% 54.39%
No. of Shareholders 5,6115,6455,8626,0646,0646,2046,2046,4966,4586,4786,5306,767

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports